Joplin Globe9 小时
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF ...
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer ...
TMCnet11 小时
Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with 29.4% CAGR ...
The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...
Artificial Intelligence in Oncology Market to Hit US$ 11.52 Billion by 2030 with 29.4% CAGR ...
The global AI in oncology market, valued at US$1.92 billion in 2023, is forecasted to grow at a robust CAGR of 29.4%, ...
Humacyte Announces FDA Approval of SYMVESS™ (acellular tissue engineered vessel-tyod) for ...
SYMVESS is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial ...